Fast-Track Robots Rewrite Vascular Care

Microbot Medical's Liberty aims to make vascular surgery faster, simpler, and more accessible.

6 Jan 2025

Microbot Medical is accelerating the launch of its single-use robotic system, Liberty, aiming to establish an early presence in vascular care. The company expects U.S. Food and Drug Administration clearance by the third quarter of 2025 and is building its domestic sales and support network in advance.

Liberty is designed to simplify vascular procedures by offering a compact, disposable and intuitive alternative to traditional robotic systems. Microbot says the device can be deployed without extensive training or costly maintenance, a combination. intended to appeal to hospitals and outpatient centres with limited resources for large-scale robotic platforms.

"We're not just launching a device, we're laying the groundwork for success before it even hits the market," said Harel Gadot, chief executive. "Hospitals need innovation that fits their workflow, not disrupts it."

The company's strategy contrasts with the gradual rollout common in the medical technology sector, focusing first on operational readiness before commercial introduction. This approach is aimed at capitalising on demand for minimally invasive procedures that promise shorter recovery times and reduced complication rates.

Analysts say adoption will depend on factors including reimbursement policies, clinical training, and evidence of long-term outcomes. The company has not yet disclosed pricing or detailed post-market evaluation plans.

Liberty's single-use format could offer infection-control advantages and eliminate the need for sterilisation between procedures, but will also require hospitals to adapt purchasing and waste management practices.

Microbot's move comes as competition in robotic-assisted surgery intensifies, with established manufacturers expanding into smaller, more versatile systems. The company is positioning Liberty as a cost-effective option that can be used in settings where conventional robots are impractical.

If approved on schedule, Liberty could be introduced into clinical practice before the end of 2025. Microbot is betting that its combination of technology and early infrastructure investment will help secure a foothold in the growing market for vascular robotics.